Asset Management and Custody Banks

Bellevue Life Sciences Acquisition

Bellevue Life Sciences Acquisition released FY2024 Cumulative 3Q earnings on November 14 (EST), with actual revenue of 0 and EPS of -0.0907

Bellevue Life Sciences Acquisition released FY2024 Q3 earnings on November 14 (EST) with actual revenue of 0 USD and EPS of -0.0599 USD

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

BLAC

Bellevue shareholders back board and approve CHF 0.15 dividend

Tip Ranks

Bellevue shareholders back board and approve CHF 0.15 dividend

IDXX

ETHZ

FRMM

LIR Life Sciences Corp. has initiated Project Phase 2 of its peptide design program in collaboration with Neuland Laboratories. This phase focuses on optimizing next-generation cell-penetrating peptides to enhance LIR's transdermal delivery platform. The program aims to identify synthetic variants that improve transport activity and manufacturability. CEO Edward Mills emphasized the importance of this phase in advancing their peptide development strategy, which seeks to provide scalable treatments for obesity through innovative drug delivery methods. The company is committed to addressing obesity with practical solutions based on established science.

StockTitan

IDEXX Labs

Ethzilla

Proshares Ultra Nasdaq Biotech

Forum Markets

LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories | BBCMF Stock News

Bellevue Healthcare Trust plc announced its unaudited net asset value (NAV) per ordinary share as of February 4, 2026. The NAV per share, including and excluding current financial year revenue items, is 143.92p. The company's portfolio investments have been valued on a bid price basis. For inquiries, contact NSM Funds (UK) Limited.

London Stock Exchange

REG - Bellevue Healthcare - Net Asset Value(s)

ATNF

SBIO

LIR Life Sciences Corp. announced positive interim results from a comparative mouse study on a CPP-enabled, needle-free delivery of GLP/GIP-based therapies. The study showed that animals treated with a novel semaglutide/CPP topical formulation had reduced blood glucose levels compared to untreated controls. This indicates that the CPP-enabled topical formulation can effectively deliver active drugs across the skin barrier, achieving sustained glucose control. The findings support further development of the transdermal platform for obesity treatments, aiming to provide alternatives to injectable drugs.

180 Life Sciences

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

SPDR S&P Biotech

iShares Biotechnology ETF

ALPS Medical Breakthrough

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies | BBCMF Stock News

Bellevue Life Sciences Acquisition(BLAC.US)

Bellevue shareholders back board and approve CHF 0.15 dividend

LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories | BBCMF Stock News

REG - Bellevue Healthcare - Net Asset Value(s)

LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies | BBCMF Stock News